Navigation Links
Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Date:8/19/2007

Interim Phase 1 Data Confirms Safety and Tolerability

PLYMOUTH MEETING, Pa., Aug. 8 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced interim data from the first Phase 1 clinical study of trodusquemine (MSI-1436) for the treatment of obesity. Anthony DelConte, M.D., Vice President, Clinical Research and Development, presented "Trodusquemine: A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders," during the IBC 12th Annual World Congress on Drug Discovery & Development of Innovative Therapeutics, August 6-8 in Boston.

The presentation summarized the clinical trial design of the single ascending dose Phase 1 study of MSI-1436 to evaluate safety and pharmacokinetics of the drug in healthy obese volunteers. Dr. DelConte provided interim data from the initial cohorts in the double-blind, randomized, placebo-controlled trial which included safety and pharmacokinetic (PK) data from 20 treated subjects and eight vehicle controls in four sequential dose groups. According to Dr. DelConte, PK profiles from the study thus far show a predictable pattern with minimal subject-to-subject variability and linearity across the range of doses studied. To date, no serious adverse events have been reported. It was emphasized that further study is needed to establish dose limiting toxicity and proof-of-concept in humans.

"These initial findings validate the preclinical safety and PK work done by Genaera scientists. We are encouraged by these findings and will continue to further characterize the safety profile and provide proof of concept for trodusquemine in obesity and type 2 diabetes management," commented Jack Armstrong, President and CEO. "We anticipate a
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Zacks.com announces the list of stocks ... analysts discuss the latest news and events impacting stocks and the ... AMGN - Free Report ), Celgene (Nasdaq: ... BIIB - Free Report ), Market Vectors Biotech ETF ... S&P Biotech ETF (AMEX: XBI - Free Report ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - ... with its strategic plan, for accelerated growth in terms ... 32.6% and revenues reached $17,862,341. Net income amounted to ... threshold for the first time in the Company,s history. ... the Company joined the forces of its subsidiaries, merging ...
(Date:10/31/2014)... 2014 Though therapies are in their nascent ... show an annual increase of 16.2% over the 2010-2020 ... billion, according to Kalorama Information,s report, Stem Cell ... therapeutics that have gained or are expected to gain ... developers tackle ever more complicated conditions, stem cell therapies ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Report: Stem Cell Technologies Market Growing 2
(Date:10/31/2014)... 31, 2014 Fundraising support for fighting cancer ... than losses. At noon on Monday, November 10 in the ... (SSMH), greater than 20 Susquehanna Health (SH) employees and community ... awareness and funds for the new Cancer Center at SSMH. ... for this act of love and support to which many ...
(Date:10/31/2014)... first study of its kind, Rice University researchers have ... cause cancer cells to become metastatic. The research reveals ... cells to both migrate and form new tumors. Researchers ... drugs that interfere with the genetic switches that cancer ... circulating tumor cells -- two of the main players ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 ... also has amazing health effects for practitioners. ... by a Doctor of Science and Movement specializing ... his dedication to pelvic floor reeducation that traditional ... urinary incontinence, Diastasis Recti, Prolepses, etc. , The ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4
... News) -- Heart disease patients with high blood pressure ... drugs (NSAIDs) are at greater risk for heart attack, ... NSAIDS include popular medications such as such as aspirin, ... are published in the July issue of The ...
... Gordon HealthDay Reporter , THURSDAY, July 14 (HealthDay News) ... you probably memorized a lot more information -- such as phone ... a new study has found that the brain just doesn,t remember ... been saved on a computer. What people may remember, however, is ...
... transplant survival more than doubled in recent years for ... Research Hospital, with patients who lacked genetically matched donors ... to be the best ever reported for leukemia patients ... expected to make transplantation a treatment option for more ...
... can be admirable or romantic. In a cancerous tumor, it ... cells that have strayed from their original location to insinuate their ... way of determining whether a newly formed tumor is more likely ... the body. In a study published in the July 12 ...
... percent of patients with primary or metastatic cancer ... seizures, confusion, difficulty swallowing and visual disturbances. These ... brain invasion from cancer called neoplastic meningitis. Santosh ... San Diego School of Medicine and colleagues have ...
... 14 (HealthDay News) -- New research suggests that training ... other people could help them overcome anxiety and prevent ... Oxford University in the United Kingdom found that training ... negative interpretations of unclear social situations could influence how ...
Cached Medicine News:Health News:Certain Painkillers May Raise Odds of Stroke, Heart Attack: Study 2Health News: Can You Google Your Memory? 2Health News: Can You Google Your Memory? 3Health News: Can You Google Your Memory? 4Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 2Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 3Health News:Early-stage melanoma tumors contain clues to metastatic potential 2Health News:Early-stage melanoma tumors contain clues to metastatic potential 3Health News:Novel combined therapy extends life, diminishes pain in brain cancer patients 2Health News:Training in Positive Thinking May Help Anxious Teens 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: